Suggested remit - to appraise the clinical and cost effectiveness of nivolumab within its marketing authorisation for treating small-cell lung cancer after platinum-based chemotherapy
Following on from information provided to NICE by the company in September 2019, the appraisal of Nivolumab for treating small-cell lung cancer after platinum-based chemotherapy [1126] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1126
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 31 October 2022 | Discontinued. Following on from information provided to NICE by the company in September 2019, the appraisal of Nivolumab for treating small-cell lung cancer after platinum-based chemotherapy [1126] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 16 September 2019 | Note added to the project documents |
| 16 September 2019 | Suspended. Referred 05/12/2016 |
| 29 November 2018 | Note added to the project documents |
| 24 September 2018 - 22 October 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 05 December 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual